Altimmune (ALT) Price & Analysis

Compare

3,600 Followers

ALT Stock Chart & Stats

$4.87

$0.16(2.19%)

At close: Jan 08 4:00 PM EST

$4.87

$0.16(2.19%)

Day’s Range― - ―

52-Week Range$2.90 - $7.73

Previous CloseN/A

Volume1.55M

Average Volume (3M)5.54M

Market Cap

$609.88M

Enterprise Value$384.48M

Total Cash (Recent Filing)$210.78M

Total Debt (Recent Filing)$15.90M

Price to Earnings (P/E)―

Beta1.67

Next Earnings

Mar 26, 2026

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding125,231,514

10 Day Avg. Volume5,608,745

30 Day Avg. Volume5,542,512

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)4.14

Price to Sales (P/S)25596.73

P/FCF Ratio-6.41

Enterprise Value/Market Cap0.63

Enterprise Value/Revenue19.22K

Enterprise Value/Gross Profit-25.74

Enterprise Value/Ebitda-4.59

Forecast

1Y Price Target

$16.00

Price Target Upside228.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy And TolerabilityPemvidutide's consistent improvements on non-invasive liver measures, coupled with meaningful weight loss and a favorable tolerability profile, support clinical differentiation in MASH development.

Financial RunwayA strong cash position and an expanded Hercules financing facility provide capital flexibility to support pivotal trial initiation and program execution without immediate funding strain.

Regulatory PathwayEnd-of-Phase 2 alignment with the FDA on key registrational parameters positions pemvidutide for a clear pivotal trial design and more constructive approval discussions.

Bears Say

Competitive PressureIntensifying competition in the MASH and weight-loss landscape increases commercial risk and requires clear clinical superiority for meaningful market uptake.

Data Limitations For DeriskingLack of repeat liver biopsies at key timepoints in existing data limits the ability to fully derisk clinical outcomes prior to launching large-scale pivotal trials.

Regulatory Endpoint RiskFDA preference for biopsy-based endpoints raises approval uncertainty because non-invasive test improvements may not substitute for required histologic confirmation.

Altimmune News

Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline

Altimmune ($ALT) has raised $75 million in new funding, giving the biotech company a boost as it continues...

12d ago

ALT

LLY

Altimmune prices $75M registered direct offering

Altimmune (ALT) “intends to use the net proceeds to fund preparation for its upcoming Phase 3 trial in...

12d ago

ALT

Altimmune initiated with an Overweight at Barclays

Barclays initiated coverage of Altimmune (ALT) with an Overweight rating and $20 price target Barclays initiated coverage of...

12d ago

ALT

Altimmune initiated with an Overweight at Barclays

Barclays initiated coverage of Altimmune (ALT) with an Overweight rating and $20 price target Published first on TheFly...

12d ago

ALT

Altimmune call volume above normal and directionally bullish

Bullish option flow detected in Altimmune (ALT) with 21,481 calls trading, 3x expected, and implied vol increasing over...

17d ago

ALT

Unusually active option classes on open January 22nd

Unusual total active option classes on open include: Odyssey Marine (OMEX), Funko (FNKO), Original BARK Company (BARK), JetBlue...

17d ago

Altimmune Sets 2026 Annual Stockholder Meeting Timeline

Altimmune ( ($ALT) ) has issued an announcement. Altimmune has scheduled its 2026 Annual Meeting of Stockholders for...

5d ago

ALT

Altimmune Announces $75 Million Registered Direct Equity Offering

Altimmune ( ($ALT) ) has shared an announcement. On January 27, 2026, Altimmune, Inc. entered into a Securities...

11d ago

ALT

Enovix, Serve Robotics, EOG, Altimmune, Globalstar Shake Markets

Insiders have been trading these 5 stocks: (($ENVX)), (($SERV)), (($EOG)), (($ALT)) and (($GSAT)). Here is a breakdown of...

29d ago

ALT

EOG

Midday Fly By: U.S. oil majors rise on Venezuela news, Versant completes spinoff

The major averages were broadly higher near noon as the markets begin their first full trading week of...

1M ago

ALT

Altimmune receives FDA breakthrough therapy designation for pemvidutide

Altimmune (ALT) announced the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) for pemvidutide, a...

1M ago

ALT

Altimmune, Pure Storage, Globalstar, Cipher Mining, AutoZone Shake-Up

Insiders have been trading these 5 stocks: (($ALT)), (($PSTG)), (($GSAT)), (($CIFR)) and (($AZO)). Here is a breakdown of...

1M ago

ALT

AZO

Altimmune’s IMPACT NASH Trial Completion Puts Pemvidutide Back in the Spotlight

Altimmune ($ALT) announced an update on their ongoing clinical study. Altimmune’s IMPACT trial, officially titled “A Phase 2,...

1M ago

ALT

Midday Fly By: Nike reports Q2 beat, TikTok to sell U.S. unit

The major averages were broadly higher near noon as the last full trading week of the year ends...

2M ago

ALT FAQ

What was Altimmune Inc’s price range in the past 12 months?

Altimmune Inc lowest stock price was $2.90 and its highest was $7.73 in the past 12 months.

What is Altimmune Inc’s market cap?

Altimmune Inc’s market cap is $609.88M.

When is Altimmune Inc’s upcoming earnings report date?

Altimmune Inc’s upcoming earnings report date is Mar 26, 2026 which is in 46 days.

How were Altimmune Inc’s earnings last quarter?

Altimmune Inc released its earnings results on Nov 06, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.272 by $0.062.

Is Altimmune Inc overvalued?

According to Wall Street analysts Altimmune Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Altimmune Inc pay dividends?

Altimmune Inc pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here

What is Altimmune Inc’s EPS estimate?

Altimmune Inc’s EPS estimate is -0.23.

How many shares outstanding does Altimmune Inc have?

Altimmune Inc has 125,231,514 shares outstanding.

What happened to Altimmune Inc’s price movement after its last earnings report?

Altimmune Inc reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.272. Following the earnings report the stock price went up 5.067%.

Which hedge fund is a major shareholder of Altimmune Inc?

Currently, no hedge funds are holding shares in ALT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Altimmune Stock Smart Score

Neutral

Fundamentals

Return on Equity

-52.61%

Trailing 12-Months

Asset Growth

47.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune (ALT) Earnings & Revenues

Historic Earnings Reports

ALT Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a positive outlook with significant financial growth, clinical progress in key trials, and strategic leadership enhancements. However, there are challenges related to the timing of clinical operations and dependency on regulatory changes, which could impact future trial designs and approvals.View all ALT earnings summaries

ALT Stock 12 Month Forecast

Average Price Target

$16.00

▲(228.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,4.8707692307692305,6.131538461538462,7.392307692307693,8.653076923076924,9.913846153846155,11.174615384615384,12.435384615384615,13.696153846153846,14.956923076923077,16.21769230769231,17.47846153846154,18.73923076923077,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,4.563076923076923,5.516153846153847,6.469230769230769,7.422307692307692,8.375384615384615,9.32846153846154,10.281538461538462,11.234615384615385,12.187692307692307,13.14076923076923,14.093846153846155,15.046923076923077,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,4.2553846153846155,4.900769230769231,5.546153846153846,6.191538461538462,6.836923076923076,7.4823076923076925,8.127692307692309,8.773076923076923,9.418461538461539,10.063846153846153,10.70923076923077,11.354615384615386,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.21,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 55, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >